Merck Drug Extends Survival in Uterine Cancer Study, Gets US Priority Review
A Merck drug extended survival in a uterine cancer study and received priority review in the United States.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.